Abstract
Prostatic steroid 5-alpha-reductase gene (SRD5A2) encodes a critical enzyme involved in the conversion of testosterone to dihydrotestosterone. A germline mis-sense substitution (A49T) leads to a variant SRD5A2 protein, which has a 5-fold higher in vitro Vmax than the wild-type protein (Ross et al, 1998; Makridakis et al, 1999). The A49T variant was recently associated with 2.5 to 3.28-fold increased risk of prostate cancer (PC) in African-American and Hispanic men (Makridakis et al, 1999). Also, Jaffe et al (2000) reported an association between A49T and more aggressive disease among Caucasian patients. Here, we report that the prevalence of the A49T variant in 449 Finnish PC patients was 6.0%, not significantly different from 6.3% observed in 223 patients with benign prostatic hyperplasia or 5.8% in 588 population-based controls (odds ratio for PC 1.04, 95% C.I. 0.62–1.76 P = 0.89). There was no association between A49T and the family history of the patients nor with tumour stage or grade. Our results argue against a prominent role of the A49T variant as a genetic risk factor for prostate cancer development and progression in the Finnish population. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN and Schaid DJ (2000) Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67: 82–91
Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wöhr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chumakov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P, Cohen D and Cussenot O (1998) Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2–43. Am J Hum Genet 62: 1416–1424
The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ and Sugimura Y (1987) The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338–362
Davis DL and Russell DW (1993) Unusual length polymorphism in the human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet 2: 820
Devgan SA, Henderson BE, Yu MC, Shi C-Y, Pike MC, Ross RK and Reichardt JKV (1997) Genetic variation of 3β-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 33: 9–12
Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH and Stampfer MJ (1999) The V89L Polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 59: 5878–5881
Ford D, Easton DF, Bishop DT, Narod SA and Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343: 692–695
Friedman LS, Szabo CI, Ostermeyer EA, Dowd P, Butler L, Park T, Lee MK, Goode EL, Rowell SE and King M-C (1995) Novel inherited mutations and variable expressivity of BRCA I alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 57: 1284–1297
Gibbs M, Stanford JL, McIndoe TA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, Miller EL, Brandzel S, Li S, Hood L and Ostrander EA (1999) Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 64: 776–787
Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters MA, Goode EL, Kolb S, Chakrabarti L, Shook M, Basom R, Ostrander EA and Hood LA (2000) Genomic scan of families with prostate cancer identifies multiple regions of interest. Am J Human Genet 67: 100–109
Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH and Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320–3323
Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW and Coetzee GA (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166–170
Irvine RA, Yu MC, Ross RK and Coetzee GA (1995) The CAG and GGC Microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937–1940
Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ and Rebbeck TR (2000) Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res 60: 1626–1630
Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M and Stampfer MJ (1997) A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 6: 189–192
Lunn RM, Bell DA, Mohler JL and Taylor JA (1999) Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20: 1727–1731
Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi C-Y, Yu MC, Henderson BE and Reichardt JKV (1997) A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductase. Cancer Res 57: 1020–1022
Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE and Reichardt JKV (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975–978
Peltonen L (1997) Molecular background of the Finnish disease heritage. Ann Med 6: 553–556
Reichardt JKV, Makridakis N, Henderson BE, Yu MC, Pike MC and Ross RK (1995) Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res 55: 3973–3975
Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN and Henderson BE (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497–4504
Smith JR, Freije D, Carpten JD, Grönberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damberg J-E, Bergh A, Emanuelsson M, Kallioniemi O-P, Walker- Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM and Isaacs WB (1996) A genome wide search reveals a major suceptibility locus for prostate cancer on chromosome 1. Science 274: 1371–1374
Suarez BK, Lin J, Burmester JK, Broman KW, Weber JL, Banerjee TK, Goddard KA, Witte JS, Elston RC and Catalona WJ (2000) A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet 66: 933–944
Syvänen AC (1998) Solid-phase minisequencing as a tool to detect DNA polymorphism. Methods Mol Biol 98: 291–298
Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL and Douglas AB (1996) Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 56: 4108–4110
Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, Bova GS, Walsh P, Isaacs W, Schleutker J, Matikainen M, Tammela T, Visakorpi T, Kallioniemi O-P, Berry R, Schaid D, French A, McDonnell S, Schroeder J, Blute M, Thibodeau S, Grönberg H, Emanuelsson M, Damber J-E, Bergh A, Jonsson B-A, Smith J, Bailey-Wilson J, Carpten J, Stephan D, Gillanders E, Amundson I, Kainu T, Freas-Lutz D, Baffoe-Bonnie A, Van Aucken A, Sood R, Collins F, Brownstein M and Trent J (1998) Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 20: 175–179
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Mononen, N., Ikonen, T., Syrjäkoski, K. et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 84, 1344–1347 (2001). https://doi.org/10.1054/bjoc.2001.1789
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1789
Keywords
This article is cited by
-
Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis
Molecular Biology Reports (2013)
-
Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate cancer
Nature Clinical Practice Urology (2005)
-
Association between hormonal genetic polymorphisms and early-onset prostate cancer
Prostate Cancer and Prostatic Diseases (2005)
-
Polymorphic changes in the KAL1 gene: Not all of them should be classified as polymorphisms
Journal of Endocrinological Investigation (2004)
-
A49T, V89L and TA repeat polymorphisms of steroid 5α-reductase type II and breast cancer risk in Japanese women
Breast Cancer Research (2002)